-
Ep. 4: Melanoma Treatment Strategy: Expert Perspectives | 28 mins
In our fourth episode of our special vodcast series, Redefining Immunotherapy: Lessons from Melanoma, our experts discuss one of the most rapidly evolving areas in melanoma care: immunotherapy treatment strategy.
Drawing on decades of combined clinical experience, the panel explores how treatment paradigms are shifting from decisions around monotherapy versus combination immunotherapy, to increasingly nuanced conversations about treatment duration, rechallenge after progression and retreatment following toxicity.
Led by Prof Georgina Long AO, the panel of experts deliver candid expert debate, practical insights and clinical nuance as they explore the evolving landscape of immunotherapy treatment decisions in melanoma care. The panel discusses:
- when to stop immunotherapy and why less treatment may sometimes be enough
- how PET complete metabolic response (CMR) is influencing treatment duration decisions
- rechallenge strategies after progression or immune-related toxicity
- managing patients after ipilimumab/nivolumab toxicity
- the growing move from adjuvant to neoadjuvant treatment approaches
The discussion also tackles the biology behind durable immune responses, the role of surveillance imaging, and the emerging concept of "definitive immunotherapy", highlighting how melanoma continues to lead the way in reshaping cancer care.
If you missed our earlier episodes, take a look here or search "Melanoma Insights" in Spotify or your favourite podcast app.
This special edition vodcast from "Melanoma Insights for Professionals" is suitable for Medical Oncologists, Oncology Nurses and other health professionals. SPEAKERS
Prof Georgina Long AO
Medical Oncologist
Melanoma Institute Australia and The University of Sydney
Declaration of Interest
A/Prof Alexander Menzies
Medical Oncologist
Melanoma Institute Australia and The University of Sydney
Declaration of Interest
A/Prof Ines Silva
Medical Oncologist
Melanoma Institute Australia
Declaration of Interest
A/Prof Matteo Carlino
Medical Oncologist
Melanoma Institute Australia and The University of Sydney
Declaration of Interest
Please note that this presentation was accurate at the time of recording (April 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.
This special vodcast is an initiative of Melanoma Institute Australia and made possible by an unrestricted educational grant from Bristol Myers Squibb.
Ep. 4: Melanoma Treatment Strategy: Expert Perspectives | 28 mins
Free
